Search results
Showing 6796 to 6810 of 8314 results
This guidance has been updated and replaced by NICE guideline CG172.
Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)
This guidance has been updated and replaced by NICE technology appraisal guidance 383.
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].
Moderately to severely active ulcerative colitis: adalimumab (ESNM6)
This evidence summary has been replaced by NICE technology appraisal guidance 329.
This evidence summary has been updated and replaced by NICE guideline NG28.
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
This guidance has been updated and replaced by NICE technology appraisal guidance 1103.
This quality standard has been updated and replaced by NICE quality standard 207.
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)
This quality standard has been updated and replaced by NICE quality standard 212.
Obesity in adults: prevention and lifestyle weight management programmes (QS111)
This quality standard has been updated and replaced by NICE quality standard 212.
This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).
This quality standard has been updated and replaced by NICE quality standard 184.
This quality standard has been updated and replaced by NICE quality standard 212.
This quality standard has been updated and replaced by NICE quality standard 211.
This quality standard has been updated and replaced by NICE quality standard 180.